Equities

Jubilant Pharmova Ltd

JUBLPHARMA:NSI

Jubilant Pharmova Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,138.50
  • Today's Change3.00 / 0.26%
  • Shares traded76.01k
  • 1 Year change+171.07%
  • Beta1.8848
Data delayed at least 15 minutes, as of Nov 22 2024 10:01 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
OPERATIONS
Net income1,7052786,304
Depreciation/depletion3,8195,5403,817
Non-Cash items3,7352,2881,978
Cash taxes paid, supplemental2,0772,0431,941
Cash interest paid, supplemental2,4372,3421,349
Changes in working capital454(1500)(3724)
Total cash from operations9,7136,6078,375
INVESTING
Capital expenditures(8977)(8144)(6000)
Other investing and cash flow items, total2,8982,7002,196
Total cash from investing(6079)(5444)(3804)
FINANCING
Financing cash flow items(2437)(2342)(1349)
Total cash dividends paid(798)(801)(801)
Issuance (retirement) of stock, net(274)(40)0
Issuance (retirement) of debt, net(816)1,6161,824
Total cash from financing(4325)(1567)(326)
NET CHANGE IN CASH
Foreign exchange effects116705573
Net change in cash(575)3014,819
Net cash-begin balance/reserved for future use10,1399,8385,020
Net cash-end balance/reserved for future use9,56410,1399,838
SUPPLEMENTAL INCOME
Depreciation, supplemental3,8195,5403,817
Cash interest paid, supplemental2,4372,3421,349
Cash taxes paid, supplemental2,0772,0431,941
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.